COMPARING THE EFFECT OF DUAL AND TRIPLE ANTIPLATELET THERAPY ON HIGH SENSITIVITY C-REACTIVE PROTEIN LEVELS IN PATIENTS WITH CORONARY ARTERY DISEASE.
Inflammation is widely considered to be an important contributing factor of the pathophysiology of Coronary Artery Disease (CAD), and the inflammatory cascade is particularly important in the atherosclerotic process. Hence High Sensitivity C-Reactive Protein (hs-CRP) is considered as the most valuable inflammatory biomarker, for they take part in the formation and progression of atherosclerotic plaque and can predict outcomes of patients with Coronary Artery Disease. Coronary artery disease patients are often prescribed with Dual (Aspirin+Clopidogrel) or Triple (Aspirin+Clopidogrel+Cilostazol) anti-platelet therapy. Several research suggest that Aspirin, Clopidogrel and Cilostazol have anti-inflammatory effect by reducing the inflammatory biomarkers such as hs-CRP,TNF-α, Interleukin-1,6.The present review is aimed to compare the effect of dual and triple antiplatelet therapy in reducing hs-CRP levels in patients with Coronary Artery Disease and thereby reducing the risk of future cardiovascular events.
KEY WORDS: Coronary Artery Disease, Dual antiplatelet therapy, Triple antiplatelet therapy, High sensitivity C-Reactive Protein.